Login to Your Account



Miravant's SnET2 Fails Phase III; Stock Price Drops 75 Percent

By Aaron Lorenzo


Tuesday, January 15, 2002
Miravant Medical Technologies Inc. suffered a 75.6 percent stock drop Monday on negative Phase III data of an investigational drug to treat vision loss.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription